Targeted treatment for remaining spots in EGFR lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding targeted radiation or surgery to your regular osimertinib treatment can better control any remaining spots of lung cancer. It is for people with a specific EGFR mutation whose cancer has shrunk but left a few active sites.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called EGFR-mutated non-small cell lung cancer (specifically the exon 19 deletion or L858R mutation).
- Your cancer is advanced (stage IV) and you are currently on osimertinib (Tagrisso) as your first treatment.
- After 3-6 months on osimertinib, a PET scan shows the disease is stable and you have 3 or fewer remaining spots (including the original tumor) that can be treated with targeted radiation or surgery.
- You are generally in good health (able to care for yourself, daily activities not limited).
- You have adequate blood counts and liver/kidney function (checked with blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests adding chemotherapy (pemetrexed and carboplatin) to the targeted drug osimertinib (Tagrisso) for people with a specific type of advanced lung cancer (EGFR-mutated adenocarcinoma) that is not controlled well by osimertinib alone. The goal is to see if the combination helps people live longer or better.
This trial tests if taking a targeted therapy drug before surgery can help shrink tumors in people with a specific type of lung cancer called EGFR-mutated squamous cell carcinoma that can be removed with surgery. The goal is to see if this approach improves outcomes.
This trial tests a new approach for patients with advanced non-small cell lung cancer that has a specific EGFR mutation (Ex19del or L858R) and has started to grow again after at least six months on osimertinib. It combines two types of focused radiation with continued osimertinib to treat only the progressing spots while keeping the rest of the disease under control.
This trial tests whether directly treating the remaining lung tumor with surgery or radiation, after initial chemo and osimertinib, can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer.
This trial tests whether adding precise, high-dose radiation (SBRT) to the targeted therapy osimertinib can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has shrunk but not disappeared on osimertinib alone.
This trial looks at using a targeted form of radiation (LAT, often like SBRT) for people whose lung cancer has spread in only a few places while on osimertinib. It aims to control those “limited progression” spots and help you stay on the same medicine longer.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.